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Abstract
Background: Acute stroke (AS) and acute myocardial infarction (AMI) share major risk factors
such as age, gender, and high blood pressure. The main objective of this study was to compare
vascular risk factor profiles with in-hospital outcomes in AS and AMI patients.
Methods:  We evaluated 486 consecutive patients who were admitted to Bjelovar General
Hospital with diagnoses of AS (ischaemic stroke or intracerebral haemorrhage; N = 380) or AMI
(N = 106) during a one year period. The frequency of risk factors and in-patient mortality rates
were assessed in both groups. For statistical analysis we used t-tests and χ2 tests.
Results: AS patients were significantly older than AMI patients: the mean age for AS patients was
68.9 ± 9.1 years, and for AMI patients was 62.8 ± 11.7 years (p < 0.001). AMI was significantly more
common than AS in patients younger than 65 years; 51% of this group had AMI and 26% had AS (p
< 0.001). Hypertension was a more common risk factor in AS patients (69% AS patients vs. 58%
AMI patients; p = 0.042). Patients who died did not differ significantly in age between the groups.
In-patient mortality rates were significantly higher in AS than AMI cases (31% vs. 12%, p < 0.001 for
all patients; 37% vs.5%, p < 0.001 for men). Women hospitalized for AMI were more likely to die
in hospital than men (28% vs. 5%; p = 0.002).
Conclusions: We found that age at the time of presentation was a significant differentiating factor
between patients with AS and AMI. The only exceptions were women, whose ages at the onset of
AS and AMI were similar. In contrast, patients who died did not differ significantly in age. We
observed significantly higher inpatient mortality for men (when adjusted for age) than for women
with AS. The five-fold higher in-patient mortality rate in women than in men with AMI is most likely
to have resulted from other factors related to treatment.
Background
Epidemiological studies [1-5] have shown that acute
stroke (AS) and acute myocardial infarction (AMI) have
common risk factors such as age, gender and hyperten-
sion, but the strength and directions of the associations
may be different. Whereas AMI is a disease caused by
ischemic changes of the myocardium, the diagnosis of AS
refers to a heterogeneous group of cerebrovascular
diseases.
Several practice guidelines for prevention and treatment
of each of these disorders have recently been published
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[2,6-9]. Furthermore, some groups have proposed plans
for regionalization of the care of AS and AMI patients [10-
13].
A substantial population of patients with AS and AMI
receive medical care in regional county hospitals. How-
ever, only a few articles [14-16] have evaluated the quality
of care in these institutions, which have limited diagnostic
and therapeutic facilities.
In our study we examined the differences in demographic
characteristics of AS and AMI patients in the county hos-
pital in Croatia, their common risk factors, and the uni-
formity of recommendations for drugs for secondary
prevention of AS and AMI at the time of discharge. We
also evaluated the in-patient mortality rates for these two
disorders.
Methods
Patients and setting
This was a retrospective study of patients admitted to
Bjelovar General Hospital. This is the only hospital in
Bjelovar-Bilogora County, which is a centrally located
region in continental Croatia, with area 2637 km2 and a
population of 144,042 inhabitants.
During a one-year period, a total of 486 consecutive
patients were admitted to the Department of Neurology
with diagnosis of AS and to the Department of Internal
Medicine with diagnosis of AMI. Demographic and clini-
cal data, laboratory results, 12-lead ECG findings, lists of
all medications and clinical outcome data were collected
from medical records and stored in our computer
database.
Definitions
Acute stroke was defined using the World Health Organi-
zation (WHO) definition [17] as "rapidly developing clin-
ical signs of focal (or global) disturbance of cerebral
function lasting more than 24 h (unless interrupted by
surgery or death) with no apparent cause other than that
of vascular origin". Patients with both ischaemic stroke
and intracerebral haemorrhage were included in the
study.
Acute myocardial infarction was diagnosed according to
the WHO definition [17] when the patients had at least
two of the following three criteria: typical chest pain for
myocardial ischaemia, initial and serial conventional elec-
trocardiographic changes in standard or precordial leads,
and enzymatic evidence of myocardial necrosis.
In-patient mortality rate was used to assess the mortality
rates of patients during hospitalization.
Risk factors
Patients with a history of hypertension in their medical
records or with three or more successive blood pressure
measurements exceeding 140/90 mmHg during hospital-
ization were considered hypertensive. Patients with left-
ventricular failure had symptoms of breathlessness
accompanied by basal crepitations, and/or a third heart
sound and radiological signs of interstitial or alveolar pul-
monary oedema. Diabetes mellitus was determined if a
history of this disease had been documented in prior med-
ical records or if patients required dietary sugar restriction,
insulin, or oral hypoglycaemic drugs during hospitaliza-
tion, in addition to the positive criteria for diabetes [18].
Therapy
Standard care for AS and AMI patients in our hospital con-
sists of monitoring vital functions, pulmonary function
support, repeated blood pressure measurement, glucose
metabolism, and fluid and electrolyte evaluation. Acetyl-
salicylic acid (ASA), hemodilution therapy and neuropro-
tective agents were used in patients with ischaemic AS.
Anti-ischaemic and antiplatelet agents were used in the
AMI patients.
Thrombolytic therapy (TT) was used only in AMI patients
who had ST-segment elevation and whose onset of disease
occurred in less than 12 h. It was administered together
with standard or low-molecular-weight heparin, which
was also used for patients without persistent ST-segment
elevation. TT was not used in the AS patients.
Frequency of use of ASA, beta-blockers, angiotensin con-
verting enzyme inhibitors, calcium blockers, and statins at
the time of discharge were also evaluated in both groups
of patients.
In general, patients with AS and AMI are hospitalized for
13 to 15 days.
Statistical analysis
Data were analyzed as mean ± SD for continuous variables
and as frequencies for variables on a nominal scale. For
group comparisons we used Student's t-test and the χ2 test
(Yates corrected test, if indicated, and Fisher exact test for
comparisons of small samples). Values of p <0.05 were
considered significant.
Results
During a one-year period, 380 patients were treated for
AS: 310 (82%) had ischaemic stroke and 70 (18%) had
intracerebral haemorrhage. There was no gender differ-
ence between the two patient groups. Urgent computer-
ized tomography (CT) was performed on 43% of patients
with AS (63% with intracerebral haemorrhage vs. 39%
with ischaemic stroke; p < 0.001).BMC Public Health 2004, 4:26 http://www.biomedcentral.com/1471-2458/4/26
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During the same year, 106 patients were treated for AMI.
The majority (N = 74, 70%) of AMI patients were men and
32 were women; p < 0.001. In contrast, there were 178
male and 202 female AS patients; p < 0.001 (Table 1). AS
patients were significantly older than AMI patients: the
mean age for AS patients was 68.9 ± 9.1 (range 30–89)
years, and for AMI patients it was 62.8 ± 11.7 (range 32–
85) years (p < 0.001). In patients younger than 65 years,
AMI was significantly more common; 51% of this group
had AMI and 26% had AS (p < 0.001).
Significant differences were found between previous myo-
cardial infarction or stroke episodes and the current dis-
ease. A history of AS was more common in patients with
current ischemic AS; 31% had suffered ischaemic stroke in
the past compared to 19% with intracerebral haemor-
rhage (p = 0.048). Also, hypertension was more common
in the AS than in the AMI group (Table 2). As anticipated,
heart failure was more common in the AMI patients.
A significantly higher number of recommendations for
ASA, statins and beta-blocking agents was found at the
time of discharge in patients with AMI than in those with
AS (Table 3).
AS patients with fatal outcome were younger than AMI
patients, but not significantly (AS patients were 69.1 ± 8.9
(range 30–86) years old, vs. 70.8 ± 11.4 (range 50–85)
years for AMI; p = 0.533). Overall, there were no signifi-
cant age differences in patients who died (Table 4).
Patients with AS had a significantly higher overall in-
patient mortality rate than those with AMI (31.1% vs.
12.3%; p < 0.001). Also, we found a significant difference
in in-patient mortality rates for men (men with AS 37.1%
vs. men with AMI 5.4%; p < 0.001) but not for women
(25.7% vs. 28.1%; p = 0.775, Table 5).
We also found a significantly higher mortality rate in
patients with intracerebral haemorrhage than with ischae-
mic stroke (54.3% vs. 25.8%; p < 0.001). In patients with
ischemic stroke, mortality in males was higher than in
females (31.5% for men vs. 20.9% for women; p = 0.047).
Table 1: Age (years) and gender of patients with acute stroke and acute myocardial infarction
Group† Gender Men vs. 
Women
Men Women
N Range Mean ± SD N Range Mean ± SD
AS 178 30–86 66.7 ± 9.4 202 39–89 70.8 ± 8.4 p* < 0.001
AMI 74 32–84 59.9 ± 11.6 32 47–85 69.7 ± 8.9 p* < 0.001
AS vs. AMI p* < 0.001 p* = 0.056
AS+AMI 252 30–86 64.7 ± 10.5 234 39–89 70.6 ± 8.5
†AS = acute stroke; AMI = acute myocardial infarction. *p value for two-sided t-test.
Table 2: Risk factors and prior medical history in patients with acute stroke and acute myocardial infarction
Risk factors Percent of patients with a risk factor and OR† (95% CI) p*
acute stroke acute myocardial infarction
Hypertension 69 58 1.62 (1.02–2.58) 0.043
Diabetes mellitus 29 25 1.22 (0.73–2.06) 0.494
Previous myocardial 
infarction
3 13 0.23 (0.10–0.55) <0.001
Previous stroke 29 9 4.39 (2.06–9.66) <0.001
Heart failure 18 31 0.50 (0.30–0.84) 0.006
Atrial fibrillation 16 10 1.65 (0.80–3.47) 0.193
* p value for Yates corrected χ2 test. †OR (95% CI) = Odds Ratio (95% confidence interval for OR).BMC Public Health 2004, 4:26 http://www.biomedcentral.com/1471-2458/4/26
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Discussion
Despite the continuing decline in the incidence of cardio-
vascular diseases (CVD) in developed countries, the inci-
dence is still increasing in developing nations [2,3,5]. In
Croatia, for example, death rates from coronary heart dis-
ease increased by over 60% in both men and women
between 1988 and 1998 [19].
In the current study, we assessed all patients admitted to
Bjelovar General Hospital during a one-year period with
Table 3: Prescribed medications in surviving patients with acute stroke (N = 262) and acute myocardial infarction (N = 93)
Medication Percent of patients at discharge who had medication and had p*
acute stroke acute myocardial infarction
Aspirin 69 84 0.007
Statins 3 14 <0.001
ACE inhibitors 76 70 0.276
Beta-blockers 2 10 0.001†
Calcium channel blockers 18 9 0.057
ACE inhibitors = angiotensin converting enzyme inhibitors. * p value for Yates corrected χ2 test. †p value for lower Fisher exact test.
Table 4: Age (years) and gender of patients who died with acute stroke or acute myocardial infarction
Group† Gender Men vs. 
Women
Men Women
N Range Mean ± SD N Range Mean ± SD
AS 66 30–85 68.0 ± 9.1 52 41–86 70.5 ± 8.4 p* = 0.137
AMI 4 50–84 66.8 ± 14.0 9 54–85 72.6 ± 10.4 p* = 0.495
AS vs. AMI p* = 0.868 p* = 0.581
AS+AMI 70 30–85 68.0 ± 9.3 61 41–86 70.8 ± 8.7
†AS = acute stroke; AMI = acute myocardial infarction. *p value for two-sided t-test.
Table 5: In-patient mortality rates according to sex and age in acute stroke and acute myocardial infarction
Group (age in years) No. of patients with the event/ No. of patients in the 
given group (%) who had
RR† (95% CI) p*
acute stroke acute myocardial infarction
Men
≤64 20/65 (30.1%) 2/48 (4.2%) 7.38 (1.81–30.09) <0.001
>64 46/113 (40.1%) 2/26 (7.7%) 5.29 (1.37–20.41) 0.001
all 66/178 (37.1%) 4/74 (5.4%) 6.86 (2.59–18.13) <0.001
Women
≤64 9/35 (25.7%) 1/6 (16.7%) 1.54 (0.24–10.07) 0.633‡
>64 43/167 (25.7%) 8/26 (30.8%) 0.84 (0.45–1.57) 0.589
all 52/202 (25.7%) 9/32 (28.1%) 0.92 (0.50–1.67) 0.775
* p value for Yates corrected χ2 test. †RR (95% CI) = relative risk for in-patient mortality rate in acute stroke vs. acute myocardial infarction. ‡p 
value for lower Fisher exact test.BMC Public Health 2004, 4:26 http://www.biomedcentral.com/1471-2458/4/26
Page 5 of 7
(page number not for citation purposes)
AS (ischaemic stroke or intracerebral haemorrhage) and
AMI.
Our data show that the number of AS patients admitted
was three times greater than the number of AMI patients.
We hypothesize that more AMI patients died at home; it
has previously been suggested that AMI is the most com-
mon cause of sudden death [20].
The number of acute CT scans performed on our hospital-
ized AS patients was relatively low, as noted in previous
reports from developing countries [21].
The majority of our AMI patients were men (70%) and
this is in agreement with other hospital based registries
[22-24]. Further, most of these patients were younger than
65 years, as in the European Network for Acute Coronary
Treatment (ENACT) group of patients [25]. In contrast,
most of our AS patients were older than 65, as reported in
other studies [14,26,27]. Nearly one half (47%) of our AS
patients were men, which is also consistent with recent
studies [26].
We found more hypertensive patients with AS, and espe-
cially with AMI, than some groups have reported
[25,26,28,29]. The frequencies of other risk factors did
not differ from those reported by other groups [14,26,27].
Hospitals vary greatly in their approaches to secondary
prevention treatment for AS patients. About 65–70% of
our AS patients received ASA and antihypertensive drugs
at the time of discharge. Only a very small proportion of
AS patients (3%) received statins. The reasons for this
were probably uncertainty about the benefit of these
drugs and their high cost [14,26,30,31].
The percentage of AMI patients who were given ASA at the
time of discharge was similar to that reported in the Euro-
pean Action on Secondary Prevention through Interven-
tion to Reduce Events II (EUROASPIRE II) study [22]. We
prescribed ACE inhibitors more frequently than reported
in EUROASPIRE II, but fewer patients were prescribed
beta-blockers and statins. Critical reviews by the EUROA-
SPIRE I and II groups [22] and Cohen [32] argued that
such inconsistency in medical practice in Europe and
North America is a major problem for reducing the risk of
recurrent disease and death.
Our data also showed an increased mortality rate for in-
patients with AS compared those with AMI. The overall
mortality rate for AMI in-patients was 12.3%, which is
similar to other studies using hospital-based registries
[33,34]. The overall mortality rate for AS in-patients was
31.1%, which is similar to the studies from Italy [35], and
Poland [36] but higher than the rates observed in Western
Europe, North America and Australia [14,21,22,25-27,37-
39]. We can partially explain this by the high prevalence
of hypertension; also, our patients had higher rates of
intracerebral haemorrhage than other groups have
reported (18% vs. <15% in Western Europe) [21]. We also
observed significantly higher inpatient mortality for men
(when adjusted for age) than for women with AS. Previ-
ous studies have indicated gender differences in outcome
for patients with CVD. Women who present with AMI are
older and have more co-morbidity than men; they are
more likely to be misdiagnosed, possibly because "atypi-
cal" symptoms can potentially delay their treatment and
diminish its aggressiveness [39]. This is associated with
higher in-patient and outpatient mortality rates for AMI.
However, for patients with AS, the influence of gender on
outcomes is controversial [40-43].
In summary, we found that age at the time of presentation
was a significant factor in patients with AS and AMI. The
only exception was that women were of similar ages at the
onset of AS and AMI. In contrast, patients who died did
not differ significantly in age. The five-fold higher in-
patient mortality rate in women than in men with AMI is
most likely to be the result of other factors related to treat-
ment. We believed that the major reasons for observed
geographical differences in hospital mortality are largely
related to methodological differences between studies
compared (e.g. local differences in approaches to hospi-
talization, availability of acute stroke services etc.).
Our study has several limitations. We assessed patients
from a single county hospital, which has particular restric-
tions; so, for example, our CT scanning rates for AS
patients were relatively low. Therefore, these findings
should not be generalized.
Our results suggest that appropriate measures are needed
to reduce the high mortality rates in our patients and to
increase the awareness of putative risk factors for patients
with cardiovascular disease. At the county level, reducing
the burden of AS and AMI will require continuous public
education and focus on controlling common risk factors,
early recognition of symptoms, and the importance of
urgent transport to the hospital. In county hospitals, there
is a burning need for easier access to health-care facilities
with better and more efficacious organization of the emer-
gency care system. Further, developing countries should
improve the management of AS and AMI in hospitals with
appropriate evaluation and early treatment of these
patients.
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